Shingrix

Phase 3Biologic

SShenzhen Shenxin Biotechnology Co., Ltd

Shingrix is one of 69 biologic programs targeting Herpes Zoster. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Herpes ZosterRecruiting

LymphomaRecruiting

Renal Transplant RecipientsRecruiting

VZVRecruiting

Allogeneic Hematopoietic Stem Cell Transplant RecipientRecruiting

Herpes ZosterPhase 2

Recruiting

LymphomaPhase 3

Recruiting

Renal Transplant RecipientsPhase 3

Recruiting

VZVPhase 3

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant RecipientPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Shingrix

SShenzhen Shenxin Biotechnology Co., Ltd

Phase 3

1 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Herpes Zoster

NCT07285265

Phase 2Recruiting

Allogeneic Hematopoietic Stem Cell Transplant Recipient

NCT05554068

Q1 2027

Phase 2Not yet recruiting

Immunogenicity

NCT07481604

Q4 2027

PreclinicalRecruiting

Herpes Zoster

NCT05580458

Phase 1/2Not yet recruiting

Herpes Zoster

NCT06801509

Phase 2Not yet recruiting

Herpes Zoster

NCT07205796

Clinical

Trials by Indication[1]

Herpes Zoster13 trials

A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

Recruiting·SShanghai Institute Of Biological Products·Phase 1/2·NCT06932523·645 enrolled

Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)

Completed·RRegion Skane·Phase 4·NCT03886038·142 enrolled

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

Active, not recruiting·IImmorna Biotherapeutics, Inc.·Phase 2·NCT06581575·467 enrolled

Show 10 more trials

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Active, not recruiting·SShenzhen Shenxin Biotechnology Co., Ltd·Phase 1·NCT06375512·150 enrolled

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

Recruiting·DDynavax Technologies Corporation·Phase 1/2·NCT06569823·764 enrolled

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

Recruiting·CCHA Vaccine Institute Co., Ltd.·Phase 1·NCT06137755·32 enrolled

A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Not yet recruiting·SShenzhen Shenxin Biotechnology Co., Ltd·Phase 2·NCT07205796·480 enrolled

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Active, not recruiting·CCurevo Inc·Phase 2·NCT05304351·1,516 enrolled

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Completed·DDynavax Technologies Corporation·Phase 1·NCT05245838·150 enrolled

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

Not yet recruiting·SSinocelltech Ltd.·Phase 1/2·NCT06801509·540 enrolled

Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above

Active, not recruiting·SSuzhou Abogen Biosciences Co., Ltd.·Phase 1·NCT07285265·180 enrolled

Phase 1/2 Open-label Trial of Safety and Zoster Immunogenicity Evaluation for People With HIV With CD4 Counts Under and Above 300 and Healthy Volunteers Following Shingrix Vaccination (ZEUS)

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT05580458·225 enrolled

A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults ≥50 Years of Age

Terminated· Moderna logo

Moderna·Phase 1·NCT05701800·659 enrolled

Immunogenicity3 trials

Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

Not yet recruiting·CCHA Vaccine Institute Co., Ltd.·Phase 2·NCT07481604·135 enrolled

Immunogenicity, Reactogenicity of Shingrix in SLE

Unknown status·SSeoul National University Hospital·Phase 3·NCT06001606·63 enrolled

A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

Completed· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Phase 1·NCT05991427·65 enrolled

Vaccine2 trials

Systems Biology of Zoster Vaccine

Completed·EEmory University·Phase 2·NCT04047979·38 enrolled

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03953196·48 enrolled

Recombinant Zoster Vaccine2 trials

The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)

Completed·JJiangsu Rec-Biotechnology Co., Ltd.·Phase 1·NCT05769049·48 enrolled

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

Active, not recruiting·GGuangzhou Patronus Biotech Co., Ltd.·Phase 1·NCT06335849·48 enrolled

COVID-191 trial

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

Completed·UUniversity of Oklahoma·Phase 1·NCT04523246·217 enrolled

13 more indications

Ulcerative Colitis1 trial

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Terminated·—·Phase 4·NCT03591770·15 enrolled

Solid Organ Transplant1 trial

Solid Organ Transplant SHINGRIX

Terminated·EEmory University··NCT03993717·2 enrolled

VZV1 trial

VZV in the Enteric Nervous System: Pathogenesis and Consequences

Recruiting·VVanderbilt University Medical Center·Phase 4·NCT05550194·40 enrolled

Memory1 trial

VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

Active, not recruiting·UUniversity of Washington·Phase 4·NCT04403139·50 enrolled

Renal Transplant Recipients1 trial

Shingrix in Renal Transplant Recipients

Recruiting·UUniversity of Colorado, Denver·Phase 3·NCT04128189·132 enrolled

Allogeneic Hematopoietic Stem Cell Transplant Recipient1 trial

Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Recruiting·LLoyola University·Phase 2·NCT05554068·100 enrolled

Inflammatory Bowel Disease1 trial

Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT03798691·33 enrolled

Shingles1 trial

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Terminated· Pfizer logo

Pfizer·Phase 2·NCT05703607·485 enrolled

Vaccination1 trial

Simultaneous RZV and aIIV4 Vaccination

Completed·—·Phase 4·NCT05007041·267 enrolled

Clinical Trial1 trial

Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years

Active, not recruiting·EEuBiologics Co.,Ltd·Phase 1·NCT06409494·72 enrolled

Rheumatic Disease1 trial

Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases

Enrolling by invitation·RRegion Skane·Phase 4·NCT06763783·240 enrolled

Lymphoma1 trial

Vaccine Responses in Patients With B Cell Malignancies

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Approved·NCT05170399·350 enrolled

Unspecified1 trial

Persistence of Protection by Shingrix

Completed·UUniversity of Colorado, Denver·Phase 4·NCT04169009·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Shingrix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Shingrix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Shingrix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Shenxin Biotechnology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: SShenzhen Shenxin Biotechnology Co., Ltd

Shingrix

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Trials by Indication[1]

Herpes Zoster13 trials

Immunogenicity3 trials

Vaccine2 trials

Recombinant Zoster Vaccine2 trials

COVID-191 trial

Ulcerative Colitis1 trial

Solid Organ Transplant1 trial

VZV1 trial

Memory1 trial

Renal Transplant Recipients1 trial

Allogeneic Hematopoietic Stem Cell Transplant Recipient1 trial

Inflammatory Bowel Disease1 trial

Shingles1 trial

Vaccination1 trial

Clinical Trial1 trial

Rheumatic Disease1 trial

Lymphoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News